Acticor Biotech Stock Quote ALACT - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

0.384

Bid

0.381

Ask

0.395

Volume

54,163

0.38 Day's Range 0.404

0.27 52 Week Range 6.22

Market Cap

5.012M

Previous Close

0.37

Open

0.389

Last Trade

312

0.384

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

76,362

Shares Outstanding

13,189,141

Dividend Yield

PE Ratio

-0.32

Earnings Per Share (EPS)

-1.2

Revenue

2.7M

Net Profit

-15.88M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.acticor-biotech.com

Headquarters

Paris, Paris, Fra

Founded

1970

Acticor Biotech is listed in the Pharmaceutical Preparations sector of the Euronext with ticker ALACT. The last closing price for Acticor Biotech was 0.37 €. Over the last year, Acticor Biotech shares have traded in a share price range of 0.27 € to 6.22 €.

Acticor Biotech currently has 13,189,141 shares outstanding. The market capitalization of Acticor Biotech is 5.01 € million. Acticor Biotech has a price to earnings ratio (PE ratio) of -0.32.

ACTICOR BIOTECH : Report de la publication des résultats annuels et du Document d’enregistrement universel 2023

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 – ALACT), entreprise biopharmaceutique au stade clinique qui développe glenzocimab, un médicament innovant pour le traitement des urgences...

ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

Analysis of the primary and secondary endpoints of the phase 2/3 ACTISAVE study showed no improved efficacy with glenzocimab Key results from this study will be presented at ESOC on May 15...

Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

Results of ACTISAVE phase 2/3 clinical study in stroke expected in Q2 2024 Presentation of results during ESOC from 15 to 17 May 2024 Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 –...

ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of March 31, 2024

Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular...

ACTICOR BIOTECH : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 29 février 2024

Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers Regulatory News: ACTICOR BIOTECH (ISIN : FR0014005OJ5 – ALACT) (Paris:ALACT), société biopharmaceutique au stade clinique...

Acticor Biotech réalise avec succès une augmentation de capital d’un montant total de 8 millions d'euros

Regulatory News: Ne pas diffuser, publier ou distribuer, directement ou indirectement, aux Etats-Unis d'Amérique, au Canada, en Australie ou au Japon. Ce communiqué de presse ne constitue pas un...

Acticor Biotech lance une augmentation de capital de 7 M€ au minimum

Augmentation de capital composée d’une offre à des investisseurs qualifiés, à des catégories d’investisseurs, ainsi qu’aux investisseurs individuels via la plateforme PrimaryBid Engagements de...

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

University of Birmingham and Acticor Biotech News ReleaseLimited clinical access available The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first...

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke

Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke 438 patients with stroke have been randomized in ACTISAVE study evaluating glenzocimab, in...

Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke

ACTICOR adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke Clinical results from ACTISAVE phase 2/3 study now expected in the second quarter...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.089	30.1694915254	0.295	0.67	0.276	589539	0.35455759	DE
4	-3.066	-88.8695652174	3.45	4.21	0.27	178191	0.55316225	DE
12	-4.016	-91.2727272727	4.4	5.3	0.27	76362	1.18637657	DE
26	-3.346	-89.7050938338	3.73	5.32	0.27	41015	1.5697593	DE
52	-4.916	-92.7547169811	5.3	6.22	0.27	20711	1.72157542	DE
156	-0.684	-64.0449438202	1.068	11	0.27	31632	2.61863253	DE
260	0.004	1.05263157895	0.38	11	0.11	64503	1.18995525	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BENFBeneficient	$ 6.8001 (254.17%)	31.01M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M
SHOTWSafety Shot Inc	$ 0.45 (45.16%)	644
AIPArteris Inc	$ 8.185 (38.03%)	1.11M
RGFReal Good Food Company Inc	$ 0.85 (37.32%)	4.26M
MNDRMobile health Network Solutions	$ 3.33 (-84.91%)	18.76M
NUVOHoldco Nuvo Group DG Ltd	$ 2.00 (-57.54%)	1.04M
SPTSprout Social Inc	$ 28.82 (-40.15%)	13.47M
UNITUniti Group Inc	$ 4.441 (-26.35%)	21.07M
IPDNProfessional Diversity Network Inc	$ 1.29 (-24.12%)	662.59k
AAPLApple Inc	$ 183.38 (5.98%)	163.22M
SQQQProShares UltraPro Short QQQ	$ 11.08 (-5.94%)	154.59M
JAGXJaguar Health Inc	$ 0.3164 (7.91%)	142.47M
NKLANikola Corporation	$ 0.6526 (6.55%)	106.88M
SGBXSafe and Green Holdings Corporation	$ 5.49 (87.37%)	92.18M